Results 171 to 180 of about 850,997 (356)
Management of pancreatic ductal adenocarcinoma (PDAC): Progress in the past decade and challenges for the future [PDF]
Roger Clementine +5 more
openalex +1 more source
Investigation into the Pancreatic Pathogenesis of SFTSV across Multiple Levels
A retrospective analysis revealed that 17.6% of severe fever with thrombocytopenia syndrome (SFTS) patients met the diagnostic criteria for clinically confirmed pancreatitis. Using human pancreatic organoids and murine models demonstrated that SFTSV exhibits a specific pancreatic tropism, leading to cell death and initiating a strong inflammatory ...
Xiaohan Liu +10 more
wiley +1 more source
c‐Rel–dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis
In response to genotoxic injury, c‐Rel upregulates ATM‐Chk2‐p53 pathway DNA damage proteins to limiting hepatocarcinogenesis. Abstract Background and Aims Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death. The NF‐κB transcription factor family subunit c‐Rel is typically protumorigenic; however, it has recently been reported as a
Jack Leslie +17 more
wiley +1 more source
Table S6 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma [PDF]
Meredith L. Stone +9 more
openalex +1 more source
Magnetoelectric nanoparticles (MENPs) serve as externally controlled, MRI‐activated theranostic agents for targeted cancer therapy by inducing electric field‐based ablation in solid tumors. MENPs enable simultaneous precise tumor ablation and MRI signal modulation, allowing real‐time treatment monitoring and prediction of therapeutic outcomes with no ...
John Michael Bryant +28 more
wiley +1 more source
TP53 R249S mutation in hepatic organoids captures the predisposing cancer risk
The systematic approach in elucidating the gain‐of‐function (GOF) roles of TP53 mutations in early liver carcinogenesis. Unique downstream targets of TP53 L3 mutations were identified from chormatin immunoprecipitation sequencing in HCC cell lines, followed by a series of validation assays to substantiate the exclusive transcriptional regulations ...
Yin Kau Lam +10 more
wiley +1 more source
Mechanism of Lenvatinib Resistance via Exosomal miRNA‐132/Nrf2 Axis in Hepatocellular Carcinoma
Exosomal miRNA‐132 from LVT‐res HCC cells activated Nrf2 expression through the PTEN/GSK3β pathway in recipient cells. This cascade could induce drug resistance in non‐resistant HCC cells in the TME. ABSTRACT Introduction Lenvatinib is a multiple receptor tyrosine kinase inhibitor and a first‐line targeted therapy for hepatocellular carcinoma (HCC ...
Chie Takasu +7 more
wiley +1 more source

